Formidable Asset Management LLC Acquires 48,252 Shares of abrdn Life Sciences Investors $HQL

Formidable Asset Management LLC raised its holdings in abrdn Life Sciences Investors (NYSE:HQL) by 63.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 124,445 shares of the company’s stock after acquiring an additional 48,252 shares during the quarter. Formidable Asset Management LLC’s holdings in abrdn Life Sciences Investors were worth $1,930,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Geneos Wealth Management Inc. grew its stake in shares of abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after purchasing an additional 1,529 shares during the last quarter. Cornerstone Advisors LLC acquired a new stake in abrdn Life Sciences Investors in the third quarter valued at $175,000. Clough Capital Partners L P bought a new position in abrdn Life Sciences Investors during the 2nd quarter worth $318,000. PMG Family Office LLC acquired a new position in abrdn Life Sciences Investors during the 3rd quarter worth about $351,000. Finally, Stephens Inc. AR lifted its holdings in abrdn Life Sciences Investors by 12.4% during the 3rd quarter. Stephens Inc. AR now owns 23,869 shares of the company’s stock worth $370,000 after buying an additional 2,638 shares during the period. Institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Trading Down 0.1%

NYSE HQL opened at $16.83 on Friday. The business’s 50-day moving average price is $16.69 and its two-hundred day moving average price is $16.57. abrdn Life Sciences Investors has a 12 month low of $10.55 and a 12 month high of $17.80.

abrdn Life Sciences Investors Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, February 20th were paid a $0.56 dividend. This is an increase from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50. This represents a $2.24 dividend on an annualized basis and a dividend yield of 13.3%. The ex-dividend date of this dividend was Friday, February 20th.

abrdn Life Sciences Investors Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.